![Ran Weinstock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ran Weinstock
Geen lopende functies
Loopbaan van Ran Weinstock
Eerdere bekende functies van Ran Weinstock
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Directeur/Bestuurslid | 31-07-2018 | - |
Independent Dir/Board Member | 31-07-2018 | - |
Opleiding van Ran Weinstock
Tel-Aviv University | Undergraduate Degree |
Netanya Academic College | Graduate Degree |
Bar-Ilan University | Graduate Degree |
Statistieken
Internationaal
Israël | 5 |
Operationeel
Graduate Degree | 2 |
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Sectoraal
Consumer Services | 4 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Beurs
- Insiders
- Ran Weinstock
- Ervaring